![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png)
ethicsiscoolAnswer:
Part 1 (Reflection): I used Claude for discussing this ethics case. I found this discussion to be much more engaging and tricky than previous ones. I think this largely has to do with the case itself surrounding a highly contentious issue. I find research ethics to be tricky, as establishing boundaries between certain ideas or considering the different areas of impact can be an extensive process. Claude forced me to think in these different directions. It made me consider things like people who have no choice but to participate in experiments, which made me think a lot about the different degrees of autonomy that are actually available to participants. I also liked that some of these questions related to what we did in the labs, and I was able to bring up the idea of RIOs and deterrents for unethical research. I think the change I made to get a much more engaging discussion was using Claude's Extended Thinking mode. Anytime I would respond to a question, it would think a for a couple of seconds before generating a response. The quality of responses were far better than with the previous case where I didn't use Extended Thinking. Thus, using the AI's thinking tools along with picking a highly contentious and rich case is the best way I've seen so far to get a thoughtful discussion going.
Part 2 (Transcript):
Me:
Teach me about ethics in scientific research using Socratic questioning. You ask me questions to guide my learning. The example under discussion is a case examining the genomic engineering tool CRISPR and some of the issues involved with making the technology widespread.[I did not include the whole copy-paste of my case from Q1 because that takes too much space, but I did show it to Claude].
Claude:
Great, let's dive in!
Question 1: When a new and powerful technology like CRISPR is developed, who do you think should have the authority to decide how it is used — scientists, governments, the public, or someone else? Why?
Me:
My immediate thought is the general public, since it was their tax dollars that helped contribute to this technology's development. The following question to answer is then how does the public have their opinion conveyed? Politicians do not always entirely reflect the interests of their people, but they are still the ones capable of making legislation that restricts this technology. In an ideal world, politicians would establish restrictions on this technology based on thorough research from a diverse (in terms of motive) group of scientists. They would minimize the severe harms of this technology like improper use while tackling legal grey areas. Then, with these restrictions, consumers and the free market would do their thing.
Claude:
That's a thoughtful answer — you've already touched on representation, public interest, and the role of regulation. Let's build on that.
Question 2: You mentioned that the public funded this technology and therefore should have a say in how it's used. One application of CRISPR involves experimenting on human embryos to better understand genetic diseases. Do you think the embryo itself has any stake in how the technology is used — in other words, do you think an embryo deserves rights or protections of its own? Why or why not?
Me:
Obviously, an embryo does not have the intelligence to make any decision yet, and the debate of whether it should have individual rights is an entirely separate and long discussion. If the regulations decide how people use this technology, then these regulations must also consider the extent to which parents can perform genetic mutations on their children. What is the fine line? What is cosmetic against what is necessary? It is a highly contentious area of debate that I feel would unfortunately get more involved with politics rather than backed research.
Claude:
You raised a great point about the fine line between cosmetic and necessary genetic modifications. That tension actually gets at a core principle in research ethics — the idea of weighing risks against benefits.
Question 3: In research ethics, scientists are generally expected to justify their work by showing that the potential benefits outweigh the potential harms. Given what you know about CRISPR, how would you go about weighing its benefits — like curing genetic diseases — against its risks, such as the possibility of it being misused for eugenics or causing unintended genetic errors?
Me:
Every technology/innovation has its risk. A powerful and faster car is more likely to experience a severe crash. A highly invasive, but possibly life-saving surgery may have a greater probability of killing someone. What matters is: how frequently the "bad case" is happening? Are errors happening 90% of the time? 60% of the time? Billions of people drive relatively fast cars (if you consider 60mph+ fast) and remain okay. Many intensive surgeries are performed and peoples' lives are saved. I believe this ties into utilitarianism: can more good be extracted from this than bad? And what shows that in this case is research and trial cases.
Claude:
Great reasoning — you've naturally arrived at a utilitarian framework, and you're right that data and research are what help us measure that balance. That leads us to an important question about how that research is actually conducted.
Question 4: You mentioned that research and trial cases are what show us whether a technology does more good than bad. But who bears the risk during that research phase — in other words, who are the subjects being experimented on, and what ethical obligations do researchers have toward them before and during experimentation?
Me:
This seems heavily related to deontological ethics. The "duty" here is not intentionally cause harm to others. Suppose we placed all responsibility on the researchers: if anything goes wrong in the experiment, they are responsible. Why would any researcher put their reputation on the line by trying something that potentially have a high risk of getting them in trouble? They don't know the potential for harm, and participants could then also exploit this (say, by placing blame on researchers for lawsuits). That narrows the responsibility down to the participants, but with some extra precautions. How is the researcher recruiting the participants? According to our "duty", they can't trick or coerce people into participating. A good solution is to practice informed consent. That way, the participant is leveraging their own autonomy. They have decided they are willing to encounter the potential harms for some greater motive of their own.
Claude:
Excellent — you independently arrived at one of the most foundational principles in research ethics: informed consent. And your reasoning about autonomy is exactly why it matters. Let's push that idea a bit further.
Question 5: You said informed consent protects participant autonomy because they willingly accept the risks. But consider this — what if the participants who volunteer for CRISPR trials are people who are desperately ill, with no other treatment options? Does desperation compromise the authenticity of that "free choice," and if so, does that create any additional ethical responsibilities for the researcher?
Me:
There are degrees of freedom to consider. The utmost degree of freedom is having the ability to not participate in this trial and still remain fine. People with lower degrees of freedom are dependent on the result of the trials. Suppose there was no trial available. Without it, there would be no potential treatment options left, and the ill would have no choice but to remain ill. A trial at least gives some chance of survival. It sounds grim and unfortunate, but I think it is better to at least be given the chance for one more shot at treatment than to be left ill. Yes, the treatment can backfire, but if anything, it gives the ill person a little bit more freedom by giving them an additional choice for something that could make them better. Researcher should respect that choice while still applying informed consent.
Claude:
You've touched on something important — that vulnerability doesn't necessarily invalidate consent, but it does change the ethical landscape. That's a nuance many researchers have to grapple with. Let's zoom out a little now.
Question 6: Throughout our discussion, we've covered informed consent, weighing risks and benefits, and protecting vulnerable participants. These are all principles that guide ethical research. But who actually enforces these principles — and what happens when a researcher, perhaps driven by ambition or the excitement of a breakthrough, decides to push boundaries without waiting for proper oversight? Can you think of what safeguards might exist, or should exist, to prevent that?
Me:
In our class we learned about RIOs (Research Integrity Officers) at universities. So I think safeguards depend on who the researchers are being managed by. If it's by a university, someone at the university should be in charge of making sure all research is conducted ethically. In a government setting, there should be some sort of equivalent role. In general, some third-party person has to be available to oversee the research in progress and stop any unethical research in its tracks. Another safeguard (more so a deterrent) against unethical research is establishing punishments for it. If any ethical violations are found, then measures like stripping researchers of their privileges (job titles) or labs of their funding should be enacted.
Claude:
Great — you've connected classroom knowledge to real-world application, and the point about consequences as a deterrent is well taken. Here's our final question to tie everything together.
Question 7: We've covered a lot of ground — public funding and accountability, informed consent, protecting vulnerable participants, weighing risks and benefits, and institutional oversight. Looking at all of these principles together, do you think the current state of CRISPR research is being handled ethically, or do you think there are gaps that still need to be addressed?
Me:
I think there is a growing concern for ensuring the research on this technology is being handled ethically. That is, there is a growing demand that this technology proves to be stable in a scientific and social sense before widespread use. Though CRISPR has been in development for a while, many of the initial concerns like eugenics or treatment failures still persist. The issues themselves are very complex to handle, technologically and ethically. I hope that this technology becomes more widespread when it has been thoroughly researched, and restricted by safeguards so that it does not cause an overreaching amount of harm. Ethical aspects still need to be addressed, but I think there is hope for this case.
Claude:
That's a thoughtful and honest reflection. You've acknowledged both the promise and the uncertainty surrounding CRISPR.
Over the course of our discussion, you independently arrived at several core principles of research ethics — utilitarian cost-benefit analysis, informed consent, protection of vulnerable populations, and institutional oversight. What this case ultimately illustrates is that ethical research isn't just about good intentions; it requires structured accountability, ongoing evaluation, and the humility to slow down when the science is moving faster than our ability to fully understand its consequences.
